Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution

Fig. 1

The treatment schedule consisted of induction chemotherapy with gemcitabine (1000 mg/m2), preoperative IMRT at 42 Gy (2.8 Gy/day, 5 times a week, 15 fractions in total), and intravenous gemcitabine administered over 30 min on days 22, 29, and 36. Radiological re-assessment was performed 4–6 weeks after the final irradiation

Back to article page